07-09-2011: Orphazyme ApS raises 14 million euro in a Series A financing round
17-05-2011: Orphazyme ApS acquires molecular chaperone technology from CytRx Corporation
17-02-2011: Orphazyme ApS raises 3 million euro in a seed round extension; Sunstone Capital joins as new investor
04-03-2010: Orphazyme ApS completes seed financing
16-01-2010: Orphazyme ApS technology published in Nature
01-07-2009: Orphazyme receives pre-seed grant from Novo Seeds
Orphazyme ApS completes seed financing
04-03-2010
Orphazyme develops pharmaceuticals that target the lysosomes. The company is dedicated to developing a novel class of therapeutics for the treatment of lysosomal storage diseases, a family of rare but debilitating disorders. Orphazyme is built on the discoveries of its scientific founders Thomas Kirkegaard Jensen and Marja Jäättela, some of which were published earlier this year in Nature.
The financing will allow the company to reach proof-of-concept for its lead clinical candidate, and support the expansion of the pipeline as well as strengthening of the IP position.
Adjunct to the financing Anders Hinsby will take the position as CEO of Orphazyme: "I am excited that Novo Seeds has decided to join as investor. Orphazyme has a very strong scientific and IP foundation due to the pioneering work of our scientific founders. The Novo Seeds investment provides us with optimal conditions for gaining momentum in developing a novel class of therapeutics for lysosomal diseases".
Henrijette Richter, Investment Director and Bobby Soni, Associate will be joining the board of Orphazyme in connection with the seed investment. They state "We have been impressed with the results Orphazyme has generated with a pre-seed grant from Novo Seeds, and we are pleased to follow this with a seed investment. Orphazyme clearly fits our investment strategy of investing in early stage Scandinavian life sciences companies based on outstanding science".
For more information about Orphazyme:
Anders Hinsby, CEO: e-mail: amh@orphazyme.com
For more information about Novo Seeds:
Henrijette Richter, Investment Director: e-mail: heri@novo.dk,
Bobby Soni, Associate: e-mail: bygs@novo.dk,
About lysosomal storage diseases
Lysosomal storage diseases are a group of approximately 40 rare genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and can result in accumulation of undegraded metabolites. Examples of lysosomal storage diseases include Gaucher's disease, Fabry's disease and Niemann-Pick disease. The symptoms and severity of lysosomal storage diseases vary, but they affect mostly children and the outcome is often death at a young age. Diagnosed incidences of individual lysosomal storage diseases are generally less than 1 in a 100.000 births, but combined the incidence rate is 1:5.000-1:10.000.
About the Investor
Novo A/S and Novo Seeds:
Novo A/S is the holding and investment company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was formed in 1999 to actively manage the assets of the foundation. It employs about 30 people and has approximately USD 15 billion of assets under management. These includes significant shareholdings in the publicly listed Novo Nordisk A/S (NYSE: NVO) and Novozymes A/S (NVZMF.PK), Novo A/S provides seed, venture and growth capital to development stage companies within life science and biotechnology, as well as manages a broad portfolio of financial assets. Novo A/S is committing up to USD 300 million annually to its investments in seed, venture and growth equity life science companies. Novo Seeds was launched in September 2007 as a new initiative from Novo A/S and the Novo Nordisk Foundation to provide funding for early stage projects and seed financing of new life science companies in Scandinavia.
The financing will allow the company to reach proof-of-concept for its lead clinical candidate, and support the expansion of the pipeline as well as strengthening of the IP position.
Adjunct to the financing Anders Hinsby will take the position as CEO of Orphazyme: "I am excited that Novo Seeds has decided to join as investor. Orphazyme has a very strong scientific and IP foundation due to the pioneering work of our scientific founders. The Novo Seeds investment provides us with optimal conditions for gaining momentum in developing a novel class of therapeutics for lysosomal diseases".
Henrijette Richter, Investment Director and Bobby Soni, Associate will be joining the board of Orphazyme in connection with the seed investment. They state "We have been impressed with the results Orphazyme has generated with a pre-seed grant from Novo Seeds, and we are pleased to follow this with a seed investment. Orphazyme clearly fits our investment strategy of investing in early stage Scandinavian life sciences companies based on outstanding science".
For more information about Orphazyme:
Anders Hinsby, CEO: e-mail: amh@orphazyme.com
For more information about Novo Seeds:
Henrijette Richter, Investment Director: e-mail: heri@novo.dk,
Bobby Soni, Associate: e-mail: bygs@novo.dk,
About lysosomal storage diseases
Lysosomal storage diseases are a group of approximately 40 rare genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and can result in accumulation of undegraded metabolites. Examples of lysosomal storage diseases include Gaucher's disease, Fabry's disease and Niemann-Pick disease. The symptoms and severity of lysosomal storage diseases vary, but they affect mostly children and the outcome is often death at a young age. Diagnosed incidences of individual lysosomal storage diseases are generally less than 1 in a 100.000 births, but combined the incidence rate is 1:5.000-1:10.000.
About the Investor
Novo A/S and Novo Seeds:
Novo A/S is the holding and investment company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was formed in 1999 to actively manage the assets of the foundation. It employs about 30 people and has approximately USD 15 billion of assets under management. These includes significant shareholdings in the publicly listed Novo Nordisk A/S (NYSE: NVO) and Novozymes A/S (NVZMF.PK), Novo A/S provides seed, venture and growth capital to development stage companies within life science and biotechnology, as well as manages a broad portfolio of financial assets. Novo A/S is committing up to USD 300 million annually to its investments in seed, venture and growth equity life science companies. Novo Seeds was launched in September 2007 as a new initiative from Novo A/S and the Novo Nordisk Foundation to provide funding for early stage projects and seed financing of new life science companies in Scandinavia.